Clinical trial
Safety and Preliminary Efficacy of Recombinant Activated Factor VII in Subjects…
NCT00123591 · Novo Nordisk A/S, Industry · Completed
Key facts
| NCT number | NCT00123591 |
|---|---|
| Title | Safety and Preliminary Efficacy of Recombinant Activated Factor VII in Subjects With Traumatic Brain Injury |
| Official title | A Randomised, Double-Blind, Placebo-Controlled, Multi-centre, Dose Escalation Study to Evaluate the Safety and Preliminary Efficacy of Recombinant Factor VIIa (NovoSeven®/NiaStase®) in Subjects With Brain Contusions |
| Lead sponsor | Novo Nordisk A/S, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Acquired Bleeding Disorder, Trauma |
| Intervention type | Drug |
| Interventions | activated recombinant human factor VII |
| Enrollment | 96 |
| Start date | Jan 1, 2005 |
| Primary completion | May 1, 2006 |
| Completion | May 1, 2006 |
| First posted | Jul 25, 2005 |
| Last update posted | Jan 12, 2017 |
| Countries | Canada, Finland, Germany, India, Israel, Italy, Netherlands, Singapore, Spain, Switzerland, Taiwan |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: